U.S. Adjustable Compression Wraps Market
Description
U.S. Adjustable Compression Wraps Market Summary
The U.S. adjustable compression wraps market size was estimated at USD 115.02 million in 2025 and is projected to reach USD 214.90 million by 2033, growing at a CAGR of 7.95% from 2026 to 2033. This growth is driven by the rising prevalence of chronic venous disorders and lymphedema, an aging population, and increasing adoption of compression therapy for post-surgical care and wound management.
The shift toward home healthcare, growing preference for easy-to-use and adjustable compression solutions, and expanding use in sports, pregnancy-related edema, and preventive care further support market expansion.
Venous leg ulcers drive the U.S. market, as compression therapy is a key component of VLU treatment and long-term management. VLU is a common complication of chronic venous insufficiency, particularly among the aging population and individuals with obesity, diabetes, or reduced mobility, leading to a large and growing patient pool. Adjustable compression wraps are preferred over traditional bandages as they provide consistent, controlled compression, are easier to apply, and support better patient adherence during prolonged treatment periods.
Pregnancy drives the market due to the high prevalence of pregnancy-related circulatory issues such as leg swelling, edema, varicose veins, and increased risk of venous insufficiency. Hormonal changes, weight gain, and increased pressure on the lower extremities during pregnancy lead healthcare providers to recommend compression therapy to improve blood circulation and reduce discomfort. Adjustable compression wraps are particularly suitable for pregnant women, as they offer flexible sizing and adjustable pressure to accommodate the body's changes throughout different stages of pregnancy. The growing awareness of maternal health, preventive care, and non-invasive management options, along with recommendations from obstetricians and midwives, is increasing the adoption of compression wraps during and after pregnancy, thereby contributing to market growth.
Sports and recreational injuries drive the market by increasing demand for supportive and recovery-focused compression solutions among athletes and physically active individuals. Muscle strains, ligament sprains, joint injuries, and soft-tissue swelling are common in sports and fitness activities. Adjustable compression wraps are widely used to reduce edema, enhance blood circulation, and promote faster recovery. Their ease of application, reusability, and ability to provide customizable compression make them particularly attractive for use during training, post-injury rehabilitation, and preventive support. In addition, growing participation in fitness, outdoor sports, and recreational activities, along with rising awareness of injury prevention and recovery management, is expanding the adoption of adjustable compression wraps beyond clinical settings into sports medicine clinics, gyms, and retail channels, thereby contributing significantly to market growth. According to the National Safety Council, following a record low number of sports and recreational injuries reported in 2020, injuries increased by 20% in 2021, 12% in 2022, 2% in 2023, and 17% in 2024.
U.S. Adjustable Compression Wraps Market Report Segmentation
This report forecasts revenue growth at the country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. adjustable compression wraps market report based on indication & pathology, end use, and distribution channel:
The U.S. adjustable compression wraps market size was estimated at USD 115.02 million in 2025 and is projected to reach USD 214.90 million by 2033, growing at a CAGR of 7.95% from 2026 to 2033. This growth is driven by the rising prevalence of chronic venous disorders and lymphedema, an aging population, and increasing adoption of compression therapy for post-surgical care and wound management.
The shift toward home healthcare, growing preference for easy-to-use and adjustable compression solutions, and expanding use in sports, pregnancy-related edema, and preventive care further support market expansion.
Venous leg ulcers drive the U.S. market, as compression therapy is a key component of VLU treatment and long-term management. VLU is a common complication of chronic venous insufficiency, particularly among the aging population and individuals with obesity, diabetes, or reduced mobility, leading to a large and growing patient pool. Adjustable compression wraps are preferred over traditional bandages as they provide consistent, controlled compression, are easier to apply, and support better patient adherence during prolonged treatment periods.
Pregnancy drives the market due to the high prevalence of pregnancy-related circulatory issues such as leg swelling, edema, varicose veins, and increased risk of venous insufficiency. Hormonal changes, weight gain, and increased pressure on the lower extremities during pregnancy lead healthcare providers to recommend compression therapy to improve blood circulation and reduce discomfort. Adjustable compression wraps are particularly suitable for pregnant women, as they offer flexible sizing and adjustable pressure to accommodate the body's changes throughout different stages of pregnancy. The growing awareness of maternal health, preventive care, and non-invasive management options, along with recommendations from obstetricians and midwives, is increasing the adoption of compression wraps during and after pregnancy, thereby contributing to market growth.
Sports and recreational injuries drive the market by increasing demand for supportive and recovery-focused compression solutions among athletes and physically active individuals. Muscle strains, ligament sprains, joint injuries, and soft-tissue swelling are common in sports and fitness activities. Adjustable compression wraps are widely used to reduce edema, enhance blood circulation, and promote faster recovery. Their ease of application, reusability, and ability to provide customizable compression make them particularly attractive for use during training, post-injury rehabilitation, and preventive support. In addition, growing participation in fitness, outdoor sports, and recreational activities, along with rising awareness of injury prevention and recovery management, is expanding the adoption of adjustable compression wraps beyond clinical settings into sports medicine clinics, gyms, and retail channels, thereby contributing significantly to market growth. According to the National Safety Council, following a record low number of sports and recreational injuries reported in 2020, injuries increased by 20% in 2021, 12% in 2022, 2% in 2023, and 17% in 2024.
U.S. Adjustable Compression Wraps Market Report Segmentation
This report forecasts revenue growth at the country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. adjustable compression wraps market report based on indication & pathology, end use, and distribution channel:
- Indication & Pathology Outlook (Revenue, USD Million, 2021 - 2033)
- Venous Leg Ulcers (VLU)
- Lymphedema
- Deep Vein Thrombosis (DVT) / Post‐thrombotic syndrome
- Chronic Venous Insufficiency
- Class 1
- Class 2
- Class 3
- Class 4
- Class 5
- Class 6
- Post-operative Edema
- Pregnancy-related Edema
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals
- Specialty Clinics
- Home healthcare
- Physician’s Office
- Nursing Homes
- Others
- Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
- Institutional Sales
- Retail Sales
Table of Contents
120 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
- Chapter 3. Immunotherapy Drugs Market Variables, Trends, & Scope
- 3.1. Market Introduction/Lineage Outlook
- 3.2. Market Size and Growth Prospects (USD Million)
- 3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
- 3.4. Immunotherapy Drugs Market Analysis Tools
- 3.4.1. Porter’s Analysis
- 3.4.1.1. Bargaining power of the suppliers
- 3.4.1.2. Bargaining power of the buyers
- 3.4.1.3. Threats of substitution
- 3.4.1.4. Threats from new entrants
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Economic and Social landscape.
- 3.4.2.3. Technological landscape
- 3.4.2.4. Environmental landscape
- 3.4.2.5. Legal landscape
- Chapter 4. Immunotherapy Drugs Market: Drug Type Estimates & Trend Analysis
- 4.1. Drug Type Market Share, 2025 & 2033
- 4.2. Drug Type Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
- 4.4. Monoclonal Antibodies
- 4.4.1. Monoclonal Antibodies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5. Immunomodulator
- 4.5.1. Immunomodulator Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6. Vaccine
- 4.6.1. Vaccine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.7. Others
- 4.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 5. Immunotherapy Drugs Market: Indication Estimates & Trend Analysis
- 5.1. Indication Market Share, 2025 & 2033
- 5.2. Indication Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
- 5.4. Cancer
- 5.4.1. Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Autoimmune Diseases
- 5.5.1. Autoimmune Diseases Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.6. Infectious Diseases
- 5.6.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.7. Others
- 5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 6. Immunotherapy Drugs Market: Regional Estimates & Trend Analysis
- 6.1. Regional Market Share Analysis, 2025 & 2033
- 6.2. Regional Market Dashboard
- 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 6.4. North America
- 6.4.1. North America Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4.2. U.S.
- 6.4.2.1. Key Country Dynamics
- 6.4.2.2. Regulatory Framework
- 6.4.2.3. Competitive Insights
- 6.4.2.4. U.S. Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4.3. Canada
- 6.4.3.1. Key Country Dynamics
- 6.4.3.2. Regulatory Framework
- 6.4.3.3. Competitive Insights
- 6.4.3.4. Canada Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4.4. Mexico
- 6.4.4.1. Key Country Dynamics
- 6.4.4.2. Regulatory Framework
- 6.4.4.3. Competitive Insights
- 6.4.4.4. Mexico Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Europe
- 6.5.1. Europe Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5.2. UK
- 6.5.2.1. Key Country Dynamics
- 6.5.2.2. Regulatory Framework
- 6.5.2.3. Competitive Insights
- 6.5.2.4. UK Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5.3. Germany
- 6.5.3.1. Key Country Dynamics
- 6.5.3.2. Regulatory Framework
- 6.5.3.3. Competitive Insights
- 6.5.3.4. Germany Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5.4. France
- 6.5.4.1. Key Country Dynamics
- 6.5.4.2. Regulatory Framework
- 6.5.4.3. Competitive Insights
- 6.5.4.4. France Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5.5. Italy
- 6.5.5.1. Key Country Dynamics
- 6.5.5.2. Regulatory Framework
- 6.5.5.3. Competitive Insights
- 6.5.5.4. Italy Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5.6. Spain
- 6.5.6.1. Key Country Dynamics
- 6.5.6.2. Regulatory Framework
- 6.5.6.3. Competitive Insights
- 6.5.6.4. Spain Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5.7. Denmark
- 6.5.7.1. Key Country Dynamics
- 6.5.7.2. Regulatory Framework
- 6.5.7.3. Competitive Insights
- 6.5.7.4. Denmark Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5.8. Sweden
- 6.5.8.1. Key Country Dynamics
- 6.5.8.2. Regulatory Framework
- 6.5.8.3. Competitive Insights
- 6.5.8.4. Sweden Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5.9. Norway
- 6.5.9.1. Key Country Dynamics
- 6.5.9.2. Regulatory Framework
- 6.5.9.3. Competitive Insights
- 6.5.9.4. Norway Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6. Asia Pacific
- 6.6.1. Asia Pacific Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.2. Japan
- 6.6.2.1. Key Country Dynamics
- 6.6.2.2. Regulatory Framework
- 6.6.2.3. Competitive Insights
- 6.6.2.4. Japan Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.3. China
- 6.6.3.1. Key Country Dynamics
- 6.6.3.2. Regulatory Framework
- 6.6.3.3. Competitive Insights
- 6.6.3.4. China Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.4. India
- 6.6.4.1. Key Country Dynamics
- 6.6.4.2. Regulatory Framework
- 6.6.4.3. Competitive Insights
- 6.6.4.4. India Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.5. Thailand
- 6.6.5.1. Key Country Dynamics
- 6.6.5.2. Regulatory Framework
- 6.6.5.3. Competitive Insights
- 6.6.5.4. Thailand Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.6. South Korea
- 6.6.6.1. Key Country Dynamics
- 6.6.6.2. Regulatory Framework
- 6.6.6.3. Competitive Insights
- 6.6.6.4. South Korea Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.7. Australia
- 6.6.7.1. Key Country Dynamics
- 6.6.7.2. Regulatory Framework
- 6.6.7.3. Competitive Insights
- 6.6.7.4. Australia Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.7. Latin America
- 6.7.1. Latin America Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.7.2. Brazil
- 6.7.2.1. Key Country Dynamics
- 6.7.2.2. Regulatory Framework
- 6.7.2.3. Competitive Insights
- 6.7.2.4. Brazil Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.7.3. Argentina
- 6.7.3.1. Key Country Dynamics
- 6.7.3.2. Regulatory Framework
- 6.7.3.3. Competitive Insights
- 6.7.3.4. Argentina Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.8. Middle East and Africa
- 6.8.1. Middle East and Africa Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.8.2. South Africa
- 6.8.2.1. Key Country Dynamics
- 6.8.2.2. Regulatory Framework
- 6.8.2.3. Competitive Insights
- 6.8.2.4. South Africa Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.8.3. Saudi Arabia
- 6.8.3.1. Key Country Dynamics
- 6.8.3.2. Regulatory Framework
- 6.8.3.3. Competitive Insights
- 6.8.3.4. Saudi Arabia Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.8.4. UAE
- 6.8.4.1. Key Country Dynamics
- 6.8.4.2. Regulatory Framework
- 6.8.4.3. Competitive Insights
- 6.8.4.4. UAE Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.8.5. Kuwait
- 6.8.5.1. Key Country Dynamics
- 6.8.5.2. Regulatory Framework
- 6.8.5.3. Competitive Insights
- 6.8.5.4. Kuwait Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 7. Competitive Landscape
- 7.1. Participant Overview
- 7.2. Company Market Position Analysis
- 7.3. Company Categorization
- 7.4. Strategy Mapping
- 7.5. Company Profiles/Listing
- 7.5.1. Amgen Inc.
- 7.5.1.1. Participant’s Overview
- 7.5.1.2. Financial Performance
- 7.5.1.3. Product Benchmarking
- 7.5.1.4. Recent Developments/ Strategic Initiatives
- 7.5.2. Novartis AG
- 7.5.2.1. Participant’s Overview
- 7.5.2.2. Financial Performance
- 7.5.2.3. Product Benchmarking
- 7.5.2.4. Recent Developments/ Strategic Initiatives
- 7.5.3. AbbVie Inc.
- 7.5.3.1. Participant’s Overview
- 7.5.3.2. Financial Performance
- 7.5.3.3. Product Benchmarking
- 7.5.3.4. Recent Developments/ Strategic Initiatives
- 7.5.4. Pfizer Inc.
- 7.5.4.1. Participant’s Overview
- 7.5.4.2. Financial Performance
- 7.5.4.3. Product Benchmarking
- 7.5.4.4. Recent Developments/ Strategic Initiatives
- 7.5.5. F. Hoffmann-La Roche Ltd
- 7.5.5.1. Participant’s Overview
- 7.5.5.2. Financial Performance
- 7.5.5.3. Product Benchmarking
- 7.5.5.4. Recent Developments/ Strategic Initiatives
- 7.5.6. Johnson & Johnson Services, Inc.
- 7.5.6.1. Participant’s Overview
- 7.5.6.2. Financial Performance
- 7.5.6.3. Product Benchmarking
- 7.5.6.4. Recent Developments/ Strategic Initiatives
- 7.5.7. AstraZeneca
- 7.5.7.1. Participant’s Overview
- 7.5.7.2. Financial Performance
- 7.5.7.3. Product Benchmarking
- 7.5.7.4. Recent Developments/ Strategic Initiatives
- 7.5.8. GSK plc.
- 7.5.8.1. Participant’s Overview
- 7.5.8.2. Financial Performance
- 7.5.8.3. Product Benchmarking
- 7.5.8.4. Recent Developments/ Strategic Initiatives
- 7.5.9. Sanofi
- 7.5.9.1. Participant’s Overview
- 7.5.9.2. Financial Performance
- 7.5.9.3. Product Benchmarking
- 7.5.9.4. Recent Developments/ Strategic Initiatives
- 7.5.10. Bayer AG
- 7.5.10.1. Participant’s Overview
- 7.5.10.2. Financial Performance
- 7.5.10.3. Product Benchmarking
- 7.5.10.4. Recent Developments/ Strategic Initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


